End-of-day quote
Taipei Exchange
03:30:00 15/05/2024 am IST
|
5-day change
|
1st Jan Change
|
53.3
TWD
|
0.00%
|
|
+1.33%
|
+6.71%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,390
|
5,921
|
6,700
|
Enterprise Value (EV)
1 |
3,184
|
5,507
|
5,514
|
P/E ratio
|
-7.91
x
|
-13.6
x
|
-19.3
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
11,88,24,390
x
|
4,50,24,74,076
x
|
21,49,49,246
x
|
EV / Revenue
|
11,16,12,921
x
|
4,18,76,56,586
x
|
17,68,91,791
x
|
EV / EBITDA
|
-9.22
x
|
-16.1
x
|
-22.3
x
|
EV / FCF
|
-1,24,64,331
x
|
-3,05,45,409
x
|
56,63,00,801
x
|
FCF Yield
|
-0%
|
-0%
|
0%
|
Price to Book
|
8.63
x
|
12
x
|
5.88
x
|
Nbr of stocks (in thousands)
|
98,832
|
1,13,642
|
1,34,142
|
Reference price
2 |
34.30
|
52.10
|
49.95
|
Announcement Date
|
16/03/22
|
21/03/23
|
26/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
1.128
|
-
|
28.53
|
1.315
|
31.17
|
EBITDA
1 |
-167.8
|
-164.9
|
-200.6
|
-345.4
|
-341.2
|
-247.5
|
EBIT
1 |
-189.9
|
-198.7
|
-233.6
|
-380
|
-377.3
|
-283
|
Operating Margin
|
-
|
-17,618.88%
|
-
|
-1,332.01%
|
-28,693.46%
|
-907.98%
|
Earnings before Tax (EBT)
1 |
-242.6
|
-198.1
|
-220.2
|
-398.4
|
-402.2
|
-300.1
|
Net income
1 |
-172
|
-197.4
|
-219.7
|
-400.9
|
-401.9
|
-322
|
Net margin
|
-
|
-17,503.1%
|
-
|
-1,405.18%
|
-30,564.41%
|
-1,032.84%
|
EPS
2 |
-3.300
|
-3.044
|
-3.120
|
-4.334
|
-3.822
|
-2.595
|
Free Cash Flow
|
-
|
-184.5
|
-80.85
|
-255.5
|
-180.3
|
9.737
|
FCF margin
|
-
|
-16,358.8%
|
-
|
-895.46%
|
-13,709.61%
|
31.24%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/05/21
|
04/05/21
|
04/05/21
|
16/03/22
|
21/03/23
|
26/02/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
345
|
77.2
|
35.7
|
206
|
414
|
1,186
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-185
|
-80.9
|
-255
|
-180
|
9.74
|
ROE (net income / shareholders' equity)
|
-
|
-56.1%
|
-97.6%
|
-135%
|
-90.6%
|
-40%
|
ROA (Net income/ Total Assets)
|
-
|
-18.4%
|
-29.5%
|
-41.3%
|
-30.1%
|
-13.6%
|
Assets
1 |
-
|
1,075
|
745.6
|
971
|
1,335
|
2,370
|
Book Value Per Share
2 |
8.710
|
3.850
|
2.020
|
3.970
|
4.340
|
8.500
|
Cash Flow per Share
2 |
6.500
|
1.190
|
0.4200
|
2.110
|
2.350
|
2.870
|
Capex
1 |
3.52
|
0.24
|
4.66
|
0.22
|
-
|
2.17
|
Capex / Sales
|
-
|
21.1%
|
-
|
0.77%
|
-
|
6.96%
|
Announcement Date
|
04/05/21
|
04/05/21
|
04/05/21
|
16/03/22
|
21/03/23
|
26/02/24
|
|
1st Jan change
|
Capi.
|
---|
| +6.71% | 22Cr | | +31.37% | 60TCr | | -2.60% | 37TCr | | +20.83% | 33TCr | | +5.69% | 29TCr | | +14.83% | 24TCr | | +9.93% | 21TCr | | -6.95% | 20TCr | | +10.77% | 17TCr | | +0.10% | 16TCr |
Other Pharmaceuticals
|